FreeTheAI

European Regulators Grant Orphan Drug Status to Quoin Pharmaceuticals Drug QRX003

BullishMedium impact
QNRX$4.15 −4.82%

European regulators have granted Orphan Drug Designation to Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) for its lead drug candidate, QRX003, as a potential treatment for Peeling Skin Syndrome. The European Medicines Agency designation marks a significant regulatory milestone for the specialty pharmaceutical company.

The status offers financial and regulatory incentives, including protocol support, reduced regulatory fees, and eligibility for European Union grants. If QRX003 eventually gains marketing authorization in Europe, the designation will provide Quoin Pharmaceuticals with ten years of market exclusivity across European markets for treating Peeling Skin Syndrome.

Quoin Pharmaceuticals plans to launch the first formal clinical study for Peeling Skin Syndrome before the end of the year. The treatment candidate has also received Pediatric Rare Disease and Fast Track designations from the U.S. Food and Drug Administration for Peeling Skin Syndrome, along with multiple designations for Netherton Syndrome across the U.S., Europe, and Japan.

Key points

  • The European Medicines Agency granted Orphan Drug Designation to QRX003 for treating Peeling Skin Syndrome.
  • Marketing approval in Europe would grant QRX003 ten years of market exclusivity for Peeling Skin Syndrome.
  • Quoin Pharmaceuticals expects to start the first formal clinical trial for Peeling Skin Syndrome before year-end.
  • The company receives incentive benefits such as fee reductions, protocol advice, and access to EU grants.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

What designation did Quoin Pharmaceuticals receive in Europe?

The European Medicines Agency granted Orphan Drug Designation to Quoin Pharmaceuticals for its drug candidate QRX003 to treat Peeling Skin Syndrome.

What benefits does European Orphan Drug Designation provide for QRX003?

It provides regulatory fee reductions, clinical trial protocol advice, EU grant access, and ten years of European market exclusivity upon receiving marketing authorization.

When will Quoin Pharmaceuticals begin clinical trials for Peeling Skin Syndrome?

Quoin Pharmaceuticals is on track to initiate the first formal clinical trial in Peeling Skin Syndrome before the end of the year.